Write a Comment
3 Comments
I am flabbergasted by this article's attempt to justify profits for GIlead. In keeping with their gross assumptions, they neglected to consider the loss of lipid benefit from TAF and consequential stent and bypass surgeries. (My absurdity is intentional to match that of these authors in Gilead's back pocket.)
does TAF worth 1000$ more than the old version?! forget it! 1) TDF patent is expiring and the old drugs will be a generic drug soon and its cost will drop of one order of magnitude 2)the new TAF is showing to be more toxic on fat metabolism than the old version. this means that it's still a kind of toxic drug. 3) Tivicay will be the next backbone therapy drug, kicking truvada out of the market, reducing costs and toxicity by a "simplified" two drugs therapy. end of the TAF story...sorry Gilead
Tom
They say, "figures don't lie, but liars figure." Look at how Abbott raised Norvir by 400% when state-funded clinical trials showed that although it was not a very good protease inhibitor, it could act as an antagonist, slowing the removal of a better drug from the system. As the prices of treatment are raised ever higher, that only gives justification to price a cure far above that. Profit margins (on manufacturing costs) are approaching 1,000-to-1. Where are the cures? Germany.
January 7, 2016 • Chicago